|1.||Locatelli, Francesco: 19 articles (01/2016 - 02/2004)|
|2.||Macdougall, Iain C: 19 articles (04/2015 - 02/2004)|
|3.||Del Vecchio, Lucia: 10 articles (01/2016 - 08/2008)|
|4.||Bohlius, Julia: 10 articles (01/2013 - 07/2008)|
|5.||Singh, Ajay K: 9 articles (09/2012 - 09/2008)|
|6.||Ludwig, Heinz: 8 articles (12/2014 - 02/2008)|
|7.||Bennett, Charles L: 8 articles (12/2013 - 02/2008)|
|8.||Casadevall, Nicole: 8 articles (04/2012 - 05/2005)|
|9.||Steensma, David P: 7 articles (10/2015 - 09/2008)|
|10.||Aapro, Matti: 7 articles (04/2013 - 02/2007)|
12/01/2013 - "Treatment with erythropoiesis-stimulating agents (ESAs) is first-line treatment for the anemia of most patients with MDS. "
01/01/2010 - "The mainstay of treatment of anemia secondary to CKD has become erythropoiesis-stimulating agents (ESAs). "
01/01/2009 - "In these patients, erythropoiesis-stimulating agents (ESAs) are effective in managing anemia but there is an increased risk for thrombovascular events. "
06/01/2008 - "Several clinical trials have established the safety and efficacy of erythropoiesis-stimulating agents in correcting anemia in patients with HF. "
05/01/2013 - "Objective improvement in exercise testing and in patient-reported QoL confirms the clinical relevance of anemia correction with erythropoiesis-stimulating agents."
|2.||Kidney Diseases (Kidney Disease)
12/01/2014 - "The introduction of erythropoiesis-stimulating agents (ESAs) markedly improved the lives of many anaemic patients with chronic kidney disease (CKD). "
12/01/2015 - "Erythropoiesis-stimulating agents (ESAs) are all effective for renal anaemia in patients with chronic kidney disease (CKD). "
05/01/2013 - "Erythropoiesis-stimulating agents (ESAs) are the mainstay of treatment in anemic chronic kidney disease (CKD) patients. "
01/01/2007 - "Erythropoiesis-stimulating agents (ESAs) are effective in the management of the anaemia of chronic kidney disease but add substantially to the treatment costs. "
09/01/2008 - "Erythropoiesis-stimulating agents (ESAs) have transformed the management of anaemia in patients with chronic kidney disease (CKD), reducing transfusion requirements and leading to improved quality of life. "
01/01/2013 - "In 2002 we conducted a meta-analysis on the effects of erythropoiesis-stimulating agents (ESAs) on overall survival in cancer patients, which suggested some evidence for improved survival in patients receiving ESAs compared with controls. "
02/01/2014 - "Second, studies are described that investigated whether erythropoiesis-stimulating agents could stimulate tumor progression in cancer patients and whether EpoR is expressed and functional on tumor cells or on endothelial cells. "
01/01/2014 - "Clinical trials with reported adverse effects of chronic erythropoiesis-stimulating agents (ESAs) treatment as well as clinical studies exploring the prognostic significance of EPO and EPOR expression in cancer patients are reviewed. "
01/01/2012 - "This became of significant concern in 2003, when some clinical trials in cancer patients reported increased tumor progression and worse survival outcomes in patients treated with erythropoiesis-stimulating agents (ESAs). "
05/01/2011 - "Recent clinical trials in cancer patients treated with erythropoiesis-stimulating agents (ESAs) and in CKD patients treated to haemoglobin (Hb) targets above the labeled range of 10-12 g/dL with ESAs raised safety concerns regarding ESA therapy. "
08/01/2010 - "Clinical studies evaluating treatment of anaemia in chronic heart failure with erythropoiesis-stimulating agents conducted so far were ofa small scale, were not controlled with placebo and usually assessed proxy parameters. "
03/01/2010 - "Despite initial studies indicating a possible beneficial effect of erythropoiesis-stimulating agents in the treatment of anemic heart failure patients, clinical trial data, to date, have failed to show convincing evidence for morbidity or mortality benefit, and information on the long-term safety is lacking. "
03/04/2014 - "This article reviews the cumulated evidence about the use of erythropoiesis-stimulating agents in congestive heart failure patients. "
03/04/2014 - "[Erythropoiesis-stimulating agents in congestive heart failure patients]."
02/01/2014 - "Erythropoiesis stimulating agents (ESAs) for congestive heart failure: the red and the black."
|5.||Myelodysplastic Syndromes (Myelodysplastic Syndrome)
01/01/2009 - "Erythropoiesis-stimulating agents are effective in myelodysplastic syndromes, but are they safe?"
06/01/2015 - "Erythropoiesis-stimulating agents (ESAs) reduce red blood cell (RBC) transfusions in approximately 40% of patients with myelodysplastic syndrome (MDS) in clinical trials. "
06/01/2013 - "A large proportion of lower-risk myelodysplastic syndromes (MDS) respond to erythropoiesis-stimulating agents (ESA), but most responses are transient. "
06/01/2013 - "Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents."
01/01/2012 - "Specialist access, financial resources and mobility are key determinants of receipt of erythropoiesis-stimulating agents among myelodysplastic syndrome patients."
|4.||darbepoetin alfa (Aranesp)
|5.||Epoetin Alfa (Epogen)
|7.||lenalidomide (CC 5013)
|9.||Biological Markers (Surrogate Marker)
|1.||Drug Therapy (Chemotherapy)
|2.||Renal Dialysis (Hemodialysis)
|3.||Blood Transfusion (Blood Transfusions)